Published in Cancer Weekly, May 29th, 2006
As part of a financing arranged with Accentia Biopharmaceuticals, Inc. (ABPI), U.S. Bank purchased $4.6 million of NMTCs as part of an investment in a subsidiary of Biovest International, Inc. (BVTI). Biovest is an Accentia subsidiary developing the cancer treatment.
The NMTC program, under the auspices of the United States Department of the Treasury, was established in 2002 to provide incentive for investing in businesses located in...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.